These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

617 related articles for article (PubMed ID: 21429433)

  • 21. Circulating angiogenic factors and urinary prolactin as predictors of adverse outcomes in women with preeclampsia.
    Leaños-Miranda A; Campos-Galicia I; Ramírez-Valenzuela KL; Chinolla-Arellano ZL; Isordia-Salas I
    Hypertension; 2013 May; 61(5):1118-25. PubMed ID: 23460287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Uteroplacental arterio-venous difference in soluble VEGFR-1 (sFlt-1), but not in soluble endoglin concentrations in preeclampsia.
    Paasche Roland MC; Lorentzen B; Godang K; Henriksen T
    Placenta; 2012 Mar; 33(3):224-6. PubMed ID: 22264588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of simvastatin, rosuvastatin and pravastatin on soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG) secretion from human umbilical vein endothelial cells, primary trophoblast cells and placenta.
    Brownfoot FC; Tong S; Hannan NJ; Hastie R; Cannon P; Kaitu'u-Lino TJ
    BMC Pregnancy Childbirth; 2016 May; 16():117. PubMed ID: 27207105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiogenic biomarkers for prediction of early preeclampsia onset in high-risk women.
    Moore Simas TA; Crawford SL; Bathgate S; Yan J; Robidoux L; Moore M; Maynard SE
    J Matern Fetal Neonatal Med; 2014 Jul; 27(10):1038-48. PubMed ID: 24066977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia.
    Baumann MU; Bersinger NA; Mohaupt MG; Raio L; Gerber S; Surbek DV
    Am J Obstet Gynecol; 2008 Sep; 199(3):266.e1-6. PubMed ID: 18771978
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Soluble endoglin for the prediction of preeclampsia in a high risk cohort.
    Maynard SE; Moore Simas TA; Bur L; Crawford SL; Solitro MJ; Meyer BA
    Hypertens Pregnancy; 2010; 29(3):330-41. PubMed ID: 20670156
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Correlation of the expressions of advanced glycation end products and its receptor in serum and placenta with the pathogenesis of preeclampsia].
    Xian N; Chen W; Zhang Y; Li J; Zhang N; Ye Y
    Zhonghua Fu Chan Ke Za Zhi; 2015 Jul; 50(7):493-9. PubMed ID: 26311638
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Placental-Specific sFLT-1 e15a Protein Is Increased in Preeclampsia, Antagonizes Vascular Endothelial Growth Factor Signaling, and Has Antiangiogenic Activity.
    Palmer KR; Kaitu'u-Lino TJ; Hastie R; Hannan NJ; Ye L; Binder N; Cannon P; Tuohey L; Johns TG; Shub A; Tong S
    Hypertension; 2015 Dec; 66(6):1251-9. PubMed ID: 26416849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension.
    Noori M; Donald AE; Angelakopoulou A; Hingorani AD; Williams DJ
    Circulation; 2010 Aug; 122(5):478-87. PubMed ID: 20644016
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies.
    Holme AM; Roland MC; Henriksen T; Michelsen TM
    Am J Obstet Gynecol; 2016 Dec; 215(6):782.e1-782.e9. PubMed ID: 27503620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. YC-1 reduces placental sFlt-1 and soluble endoglin production and decreases endothelial dysfunction: A possible therapeutic for preeclampsia.
    Brownfoot FC; Tong S; Hannan NJ; Hastie R; Cannon P; Tuohey L; Kaitu'u-Lino TJ
    Mol Cell Endocrinol; 2015 Sep; 413():202-8. PubMed ID: 26159901
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibiting trophoblast PAR-1 overexpression suppresses sFlt-1-induced anti-angiogenesis and abnormal vascular remodeling: a possible therapeutic approach for preeclampsia.
    Zhao Y; Zheng Y; Liu X; Luo Q; Wu D; Liu X; Zou L
    Mol Hum Reprod; 2018 Mar; 24(3):158-169. PubMed ID: 29325127
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An analysis on the roles of angiogenesis-related factors including serum vitamin D, soluble endoglin (sEng), soluble fms-like tyrosine kinase 1 (sFlt1), and vascular endothelial growth factor (VEGF) in the diagnosis and severity of late-onset preeclampsia.
    Cim N; Kurdoglu M; Ege S; Yoruk I; Yaman G; Yildizhan R
    J Matern Fetal Neonatal Med; 2017 Jul; 30(13):1602-1607. PubMed ID: 27658884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum sFlt1:PlGF ratio, PlGF, and soluble endoglin levels in gestational proteinuria.
    Ohkuchi A; Hirashima C; Matsubara S; Suzuki H; Takahashi K; Usui R; Suzuki M
    Hypertens Pregnancy; 2009 Feb; 28(1):95-108. PubMed ID: 19165674
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activating Transcription Factor 3 Is Reduced in Preeclamptic Placentas and Negatively Regulates sFlt-1 (Soluble fms-Like Tyrosine Kinase 1), Soluble Endoglin, and Proinflammatory Cytokines in Placenta.
    Kaitu'u-Lino TJ; Brownfoot FC; Hastie R; Chand A; Cannon P; Deo M; Tuohey L; Whitehead C; Hannan NJ; Tong S
    Hypertension; 2017 Nov; 70(5):1014-1024. PubMed ID: 28947613
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlations between circulating levels of adipokines and anti-angiogenic factors in women with BMI <30 and a late-onset preeclampsia.
    Eleuterio NM; Palei AC; Rangel Machado JS; Tanus-Santos JE; Cavalli RC; Sandrim VC
    Hypertens Pregnancy; 2014 Feb; 33(1):72-80. PubMed ID: 24380505
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.
    Levine RJ; Lam C; Qian C; Yu KF; Maynard SE; Sachs BP; Sibai BM; Epstein FH; Romero R; Thadhani R; Karumanchi SA;
    N Engl J Med; 2006 Sep; 355(10):992-1005. PubMed ID: 16957146
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Relationship between the expression of human leukocyte antigen G and preeclampsia].
    Zhao SC; Li ZB; He TQ; Yu CZ
    Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):758-62. PubMed ID: 22321350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Relationship between pigment epithelium-derived factor expressed in placentas and the pathogenesis of preeclampsia disease].
    Wu Y; Yu YH; Zhong M; Gong SP; Li Q; Liu SS
    Zhonghua Fu Chan Ke Za Zhi; 2013 Jul; 48(7):490-3. PubMed ID: 24284217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1.
    Cudmore M; Ahmad S; Al-Ani B; Fujisawa T; Coxall H; Chudasama K; Devey LR; Wigmore SJ; Abbas A; Hewett PW; Ahmed A
    Circulation; 2007 Apr; 115(13):1789-97. PubMed ID: 17389265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.